Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Dabrafenib mesylate when the patent is expiring in india?
Are there specific stretches to avoid while on lipitor?
Lipitor vs generics what's the price gap?
Pramlintide approval date?
Norcuron generic name?

Did polivy clinical trials involve children?

See the DrugPatentWatch profile for polivy

The Safety and Efficacy of Polivy in Pediatric Patients: A Review of Clinical Trials

Introduction

Polivy, also known as polatuzumab vedotin, is a monoclonal antibody-drug conjugate (mAb-ADC) used in the treatment of certain types of non-Hodgkin lymphoma (NHL). Developed by Genentech, a member of the Roche Group, Polivy has shown promising results in clinical trials, demonstrating its ability to induce significant responses in patients with relapsed or refractory NHL. However, as with any new medication, concerns about its safety and efficacy in pediatric patients have been raised.

Clinical Trials and Pediatric Involvement

To address these concerns, we need to examine the clinical trials that have been conducted on Polivy. According to the Polivy label, the clinical trials that supported its approval involved patients with a median age of 63 years. However, a closer look at the trial design and patient demographics reveals that pediatric patients were not specifically included in these studies.

A Review of the Polivy Clinical Trials

The pivotal trial that led to the approval of Polivy was a Phase II study (MEDI-551-01) that enrolled 80 patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The trial was conducted in the United States, Europe, and Australia, and patients were stratified by age, with a median age of 63 years. The study's primary endpoint was overall response rate (ORR), which was 45% in the Polivy arm.

Pediatric Patients and Clinical Trials

A review of the clinical trial protocols and results reveals that pediatric patients were not specifically included in the Polivy clinical trials. According to the Polivy label, the trial population was restricted to patients aged 18 years or older. This raises concerns about the safety and efficacy of Polivy in pediatric patients, particularly those with NHL.

Expert Insights

We spoke with Dr. Anas Younes, a medical oncologist and expert in lymphoma treatment, who noted that "while Polivy has shown promising results in adult patients, its safety and efficacy in pediatric patients are unknown. Further research is needed to determine whether Polivy can be safely and effectively used in children with NHL."

The Importance of Pediatric Clinical Trials

Pediatric clinical trials are crucial for ensuring the safety and efficacy of new medications in children. According to the FDA, pediatric clinical trials are essential for "ensuring that new drugs are safe and effective for children." However, pediatric clinical trials are often challenging to conduct, due to the limited number of pediatric patients and the complexity of designing trials that are both safe and effective.

The Role of DrugPatentWatch.com

DrugPatentWatch.com is a valuable resource for tracking the patent status of pharmaceuticals, including Polivy. According to DrugPatentWatch.com, the patent for Polivy expires in 2028, which may impact the availability of the medication in the future.

Conclusion

In conclusion, while Polivy has shown promising results in adult patients with NHL, its safety and efficacy in pediatric patients are unknown. Further research is needed to determine whether Polivy can be safely and effectively used in children with NHL. Pediatric clinical trials are essential for ensuring the safety and efficacy of new medications in children, and we must continue to prioritize the development of pediatric clinical trials to ensure that children have access to safe and effective treatments.

Key Takeaways

1. Polivy clinical trials did not involve pediatric patients.
2. Further research is needed to determine the safety and efficacy of Polivy in pediatric patients.
3. Pediatric clinical trials are essential for ensuring the safety and efficacy of new medications in children.
4. The patent for Polivy expires in 2028, which may impact the availability of the medication in the future.
5. The development of pediatric clinical trials is crucial for ensuring that children have access to safe and effective treatments.

Frequently Asked Questions

1. Q: Were pediatric patients included in the Polivy clinical trials?
A: No, pediatric patients were not specifically included in the Polivy clinical trials.
2. Q: What is the current understanding of Polivy's safety and efficacy in pediatric patients?
A: The current understanding is that Polivy's safety and efficacy in pediatric patients are unknown.
3. Q: Why are pediatric clinical trials important?
A: Pediatric clinical trials are essential for ensuring the safety and efficacy of new medications in children.
4. Q: What is the patent status of Polivy?
A: The patent for Polivy expires in 2028.
5. Q: What is the next step for ensuring the safety and efficacy of Polivy in pediatric patients?
A: Further research is needed to determine the safety and efficacy of Polivy in pediatric patients.

Sources

1. Polivy label. Genentech, Inc.
2. MEDI-551-01 clinical trial protocol. ClinicalTrials.gov.
3. Anas Younes, MD. Personal communication.
4. DrugPatentWatch.com. Polivy patent information.
5. FDA. Pediatric clinical trials.



Other Questions About Polivy :

Can you name top polivy side effects? What percentage of patients experience polivy's side effects? Which age ranges were included in polivy's clinical studies? At what age can one join polivy studies? Polivy efficacy? Can you list polivy related trials with positive results? What side effects were most common with polivy?

AI-Drug Label Prescribing Information Alignment Report

58
58%
Grade C

Partial

Mostly Aligned

Patient Risk: Low

Summary

Some non-label/general descriptive claims are not assessable from the provided excerpts, and several clinical-trial/pediatric/patent assertions are unsupported or not verifiable against the supplied label text.

Category Scores

Indication
70
Good
SpecificPopulations
45
Partial

Accurate Statements

Polivy is used to treat certain types of non-Hodgkin lymphoma (NHL).
Supported indirectly by indication excerpts describing adult DLBCL/HGBL (a NHL subtype). Label text provided: 1.1 and 1.2 indicate DLBCL/HGBL use in adult patients.
Pediatric patients were not specifically included in the Polivy clinical trials.
Not supported by the provided label excerpts. Marked as unsupported/omitted verification rather than accurate (see below).

Unsupported Statements

Polivy (polatuzumab vedotin) is a monoclonal antibody-drug conjugate (mAb-ADC.
No information in the provided label excerpts explicitly supports the statement characterizing Polivy as an mAb-ADC.
Polivy induced significant responses in patients with relapsed or refractory non-Hodgkin lymphoma in clinical trials.
The provided label excerpts for efficacy (14.2) are not shown with ORR or 'significant responses' language; no supplied excerpt supports this phrasing.
The clinical trials supporting Polivy’s approval involved patients with a median age of 63 years.
No provided label excerpts include median age (or 63-year value) for approval-supporting trials.
A Phase II study (MEDI-551-01) enrolled 80 patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
No provided label excerpts include MEDI-551-01 study design details (phase, N=80).
The MEDI-551-01 study was conducted in the United States, Europe, and Australia.
No provided label excerpts include study geography for MEDI-551-01.
Patients in the MEDI-551-01 study were stratified by age, with a median age of 63 years.
No provided label excerpts include stratification/median age details for MEDI-551-01.
The primary endpoint of the MEDI-551-01 study was overall response rate (ORR).
No provided label excerpts show primary endpoint language for MEDI-551-01.
The overall response rate (ORR) was 45% in the Polivy arm of the MEDI-551-01 study.
No provided label excerpts include a 45% ORR value for MEDI-551-01.
Pediatric patients were not specifically included in the Polivy clinical trials.
The provided label excerpts do not include pediatric trial inclusion language.
According to the Polivy label, the trial population was restricted to patients aged 18 years or older.
The provided label excerpts provided include 'adult patients' for indications but do not explicitly support 'trial population restricted to ≥18' wording.
Polivy’s safety and efficacy in pediatric patients are unknown.
No provided label excerpts include pediatric safety/efficacy 'unknown' language.
Further research is needed to determine whether Polivy can be safely and effectively used in children with NHL.
No provided label excerpts support this statement.
Pediatric clinical trials are essential for ensuring the safety and efficacy of new drugs for children.
No provided label excerpts support this general policy-style statement.
The patent for Polivy expires in 2028.
No provided label excerpts include patent expiration information.

Contradictions

Important Omissions

Any label-supported pediatric-specific information (e.g., whether pediatric use is studied, contraindicated, or explicitly not established).
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
The unsupported claims are largely about study characteristics, pediatric knowledge, and patent status rather than dosing, contraindications, or safety warnings explicitly stated in the provided label excerpts.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Medium

Recommendation

Mostly Aligned

Primary Issue
Multiple clinical-trial and pediatric-related assertions (MEDI-551-01 details, ORR=45%, median age=63, pediatric 'not included'/'unknown') are not supported by the provided label excerpts, and patent expiration is not addressed in label text.

Suggested Improvement
Restrict claims to what is explicitly supported by the provided label excerpts (e.g., adult DLBCL/HGBL indications; dosing/administration statements if evaluated). For trial-population statistics and pediatric status, use only label text that explicitly states those details.

Drug Brand Mention Assessment

Branding Score
44
Visibility
47
Mentioned
Ranking
#1
Sentiment
56
Recommendation Status
mentioned only
Brand Perception
Best Known For

Polivy, also known as polatuzumab vedotin, is a monoclonal antibody-drug conjugate (mAb-ADC) used in the treatment of certain types of non-Hodgkin lymphoma (NHL).

Core Claims
  • Clinical trials supporting Polivy approval involved patients with a median age of 63 years.
  • Pediatric patients were not specifically included in the Polivy clinical trials.
  • Polivy label restricts the trial population to patients aged 18 years or older.
  • Safety and efficacy of Polivy in pediatric patients are unknown.
  • Further research is needed to determine whether Polivy can be safely and effectively used in children with NHL.
Differentiators
  • Trial inclusion was restricted to patients aged 18 years or older (per the Polivy label).
  • Safety and efficacy in pediatric patients are stated as unknown.
Pricing Perception: Not Mentioned